查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2003218

獸用鎮靜劑市場：2026-2032年全球市場預測（依產品類型、動物類型、應用、通路和最終用戶分類）

Animal Sedative Market by Product Type, Animal Type, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物鎮靜劑市場價值將達到 2.0656 億美元，到 2026 年將成長到 2.2344 億美元，到 2032 年將達到 3.1427 億美元，複合年成長率為 6.17%。

主要市場統計數據
基準年 2025 2.0656億美元
預計年份：2026年 2.2344億美元
預測年份：2032年 3.1427億美元
複合年成長率 (%) 6.17%

概述了不斷變化的臨床需求、監管考慮因素以及製劑技術的進步，這些因素正在重塑獸醫學各個方面鎮靜劑的選擇和使用。

隨著獸醫學的進步與不斷變化的臨床需求和監管審查相結合，動物鎮靜療法的格局正在迅速變化。臨床醫生越來越需要兼顧療效和安全性的藥物，以適用於不同類型的動物和各種手術；而飼主和醫療機構相關人員則希望獲得可預測的行為和生理反應，以支持診斷、手術和日常護理。同時，製劑和給藥途徑的創新正在為診所和實踐拓展更多實際選擇，進一步凸顯了實證鎮靜劑選擇和合理使用的重要性。

臨床實踐的現代化、監管的加強以及數位技術和供應鏈的創新，是如何共同重新定義獸醫鎮靜劑生產商和診所的成功因素的？

動物鎮靜劑市場格局正受到多項變革性變化的影響，這些變化遠不止於產品創新。在臨床實踐中，治療方案正轉向多管齊下，將鎮靜劑與鎮痛藥和抗焦慮藥聯合使用，以在保持療效的同時最大限度地減少藥物劑量，從而提高安全性和恢復率。同時，監管機構對精神藥物及其在牲畜體內殘留限量的關注度不斷提高，迫使生產商最佳化標籤、制定停藥期指南並加強供應鏈可追溯性，以維持市場准入和臨床醫生的信任。

本研究評估了關稅波動和貿易政策趨勢如何影響獸用鎮靜劑利害關係人的供應鏈選擇、採購行為和長期策略定位。

貿易政策的調整和關稅的變化對獸藥採購趨勢有顯著的影響。關稅會改變進口總成本，促進本地化生產，並影響品牌藥和非專利藥的選擇，尤其對於用量較大的鎮靜劑和對溫度敏感的鎮靜劑而言更是如此。當進口關稅上漲時，批發商和診所可能會優先選擇國產製劑，或簽訂長期合約以避免價格波動的影響。這反過來又會影響生產商的市場准入和投資策略。

細分市場洞察揭示了不同的產品類型、動物類型、應用和分銷管道如何影響臨床選擇、商業策略和最終用戶期望。

對細分市場的深入理解有助於更透徹地洞察產品性能和商業性機會。產品類型著重於每種給藥途徑獨特的操作特性和臨床醫生的偏好，例如吸入劑、注射和口服製劑。起效時間、持續時間、給藥便利性和監測負擔等因素會影響所有醫療機構的臨床應用。動物類型也至關重要，因為伴侶動物、馬匹和牲畜的治療需求差異顯著，導致製劑、給藥指南以及殘留和清除方面的考量重點不同，進而影響臨床通訊協定設計和監管標籤。

從跨區域觀點探討管理體制、臨床實務成熟度和文化態度對美洲、歐洲、中東和非洲以及亞太地區產品策略的影響。

區域趨勢持續影響鎮靜劑的臨床實踐、法規結構和商業模式。在美洲，成熟的獸醫基礎設施和強大的私立動物醫院網路推動了對先進製劑和獸醫服務的需求，而監管監督和相關人員的期望則強調藥物安全檢測和受管製藥物的管理。歐洲、中東和非洲的差異尤其顯著。歐洲部分地區嚴格的法規和動物福利標準與中東和非洲某些司法管轄區新興市場的需求形成鮮明對比，影響著進入模式、定價策略和臨床指南的協調統一進程。

決定鎮靜劑領域產品差異化和市場進入有效性的關鍵競爭和合作趨勢，涉及製造商、經銷商和臨床相關人員。

動物鎮靜劑市場的競爭格局既有老牌動物用藥品藥廠，也有高度專業化、創新公司。業界領導企業強調完善的臨床試驗項目、全面的安全性數據和強力的監管文件，以吸引獸醫和機構負責人採用其產品。同時，一些反應敏捷的公司正在開發特色配方、新型給藥途徑和配套診斷工具，力求透過易用性、安全性和物種特異性來脫穎而出。

製造商、經銷商和臨床領導者採用的可操作策略重點，專注於證據建構、供應鏈韌性、監管合作以及針對分銷管道最佳化的商業化。

該領域的領導者應優先考慮平衡策略，將臨床證據的累積、監管前瞻性和供應鏈韌性相結合。投資於嚴謹的對比研究和真實世界數據能夠增強產品價值提案，並促進指南的採納。同時，積極與監管機構合作，重點關注標籤、肉類殘留管理和藥品監管合規性，可以降低市場准入風險，增強相關人員的信心。在營運方面，建立多元化的製造地和開發緊急採購系統可以減輕貿易政策變化和關稅波動的影響。

該文件清楚地解釋了混合方法研究途徑，該方法結合了對從業人員的訪談、臨床文獻、監管審查和交叉檢驗，以確保研究結果的穩健性和可重複性。

本分析採用混合方法，將一手質性資料與嚴謹的二手研究結合，以確保全面涵蓋並檢驗的結論。一手研究包括對執業獸醫、臨床藥理學家、分銷主管和採購專家進行結構化訪談，以收集關於產品性能、採購限制和不斷發展的臨床通訊協定的第一手觀點。這些發現與同行評審文獻、監管指導文件和產品標籤等二級資訊來源進行交叉比對，以檢驗臨床聲明和安全性考慮因素。

將策略挑戰和實際影響相結合，強調證據一致性、監管準備和分銷靈活性是實現永續成功的驅動力。

這些研究結果共同表明，動物鎮靜劑領域的成功取決於臨床療效、監管合規性和可操作的分銷實踐之間的協調一致。相關人員必須保持營運彈性，以應對供應鏈和關稅相關的風險，同時也要兼顧物種特異性要求、應用特定績效預期以及區域性管理體制的差異。將實證實踐與臨床醫生教育和通路特定的商業化策略相結合，對於促進產品滲透和確保長期的臨床及商業性永續性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：動物鎮靜劑市場：依產品類型分類

  • 吸入劑
  • 注射藥物
  • 口服

第9章：動物鎮靜劑市場：依動物類型分類

  • 伴侶動物
  • 馬
  • 家畜

第10章：動物鎮靜劑市場：依應用領域分類

  • 行為管理
  • 診斷治療
  • 外科手術

第11章：動物鎮靜劑市場：依通路分類

  • 網路藥房
  • 零售藥房
  • 動物診所
  • 動物醫院

第12章：動物鎮靜劑市場：依最終用戶分類

  • 研究機構
  • 動物診所
  • 動物用藥品批發商
  • 動物醫院

第13章：動物鎮靜劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：動物鎮靜劑市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：動物鎮靜劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國獸用鎮靜劑市場

第17章：中國動物鎮靜劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aspen Veterinary Resources, Ltd.
  • Bayer AG
  • Bimeda Holdings PLC
  • Ceva Sante Animale
  • Chanelle Pharma Group
  • Dechra Pharmaceuticals PLC
  • Huvepharma EOOD
  • Jurox Pty Ltd.
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Orion Corporation
  • Vetoquinol SA
  • Virbac SA
  • Vetoquinol SA
  • Wildlife Pharmaceuticals, Inc.
  • Zoetis Inc.
Product Code: MRR-8652FEF459B1

The Animal Sedative Market was valued at USD 206.56 million in 2025 and is projected to grow to USD 223.44 million in 2026, with a CAGR of 6.17%, reaching USD 314.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 206.56 million
Estimated Year [2026] USD 223.44 million
Forecast Year [2032] USD 314.27 million
CAGR (%) 6.17%

An overview of changing clinical demands regulatory considerations and formulation advances that are reshaping selection and use of sedative agents across veterinary care settings

The therapeutic and procedural landscape for animal sedatives has evolved rapidly as advances in veterinary practice intersect with shifting clinical expectations and regulatory scrutiny. Clinicians increasingly demand agents that balance efficacy with safety across diverse species and procedures, while owners and institutional stakeholders seek predictable behavioral and physiological responses to support diagnostic, surgical, and routine care. Meanwhile, innovation in formulation and delivery routes has expanded practical options in clinics and field settings, amplifying the importance of evidence-driven selection and stewardship of sedative agents.

Against this backdrop, the industry must reconcile the need for effective sedation protocols with heightened emphasis on animal welfare, drug residue considerations in food-producing species, and the operational imperatives of veterinary service providers. These dynamics are driving a more data-centric approach to product adoption, where comparative performance, handling logistics, and compatibility with multimodal analgesia inform procurement and clinical guidelines. As a result, manufacturers, distributors, and clinical leaders are recalibrating strategies to align with both practitioner preferences and regulatory expectations across markets.

How clinical practice modernization regulatory tightening and digital and supply chain innovations are jointly redefining manufacturer and clinic success factors in veterinary sedation

The market environment for animal sedatives is being reshaped by several transformative shifts that extend beyond simple product innovation. Clinical practice has moved toward multimodal approaches that integrate sedatives with analgesics and anxiolytics to minimize drug doses while preserving efficacy, thereby improving safety margins and recovery profiles. Concurrently, heightened regulatory attention on controlled substances and residue limits in livestock has pressured manufacturers to optimize labeling, withdrawal guidance, and supply chain traceability to maintain market access and clinician confidence.

Technological and operational shifts are also evident. Digital tools for dosing calculations, teleconsultation platforms for remote behavioral assessment, and electronic medical records are enabling more consistent application of sedation protocols and facilitating post-procedure monitoring. In parallel, supply chain modernization-driven by e-commerce channels, integrated distribution partnerships, and temperature-controlled logistics-has altered product availability and the speed of clinical adoption. Taken together, these developments are creating an ecosystem where clinical efficacy, regulatory compliance, and logistical reliability are equally critical for long-term success.

Evaluating how tariff shifts and trade policy developments are influencing supply chain choices procurement behavior and long-term strategic positioning for veterinary sedative stakeholders

Trade policy adjustments and tariff movements have a measurable influence on the procurement dynamics of pharmaceutical supplies used in veterinary practice. Tariffs can change landed costs, incentivize localization of production, and affect the choice between branded and generic products, particularly for high-volume or temperature-sensitive sedatives. When import duties rise, distributors and clinics may prioritize domestically produced formulations or negotiate longer-term contracts to insulate against price volatility, which in turn affects manufacturers' market entry and investment strategies.

In addition, tariff-driven cost pressures often prompt supply chain diversification. Companies may seek alternative sourcing routes, shift manufacturing footprints, or restructure distribution models to maintain margin integrity and ensure continuity of supply. Downstream, veterinary service providers adjust inventory policies and clinical protocols to reflect changes in product availability and cost. These responses emphasize the importance of proactive trade policy monitoring and scenario planning so that stakeholders can mitigate disruption, preserve clinical standards, and sustain access to essential sedative agents across care settings.

Segment-driven insights that clarify how distinct product types animal classes applications and distribution pathways shape clinical choices commercial strategies and end-user expectations

A granular understanding of segmentation deepens insight into product performance and commercial opportunity. Based on Product Type, attention centers on the distinct operational characteristics and clinician preferences for Inhalant, Injectable, and Oral modalities, where considerations such as onset time, duration, ease of administration, and monitoring burden shape clinical adoption across settings. Based on Animal Type, therapeutic demands vary substantially among Companion Animals, Equine, and Livestock, creating divergent priorities in formulation, dosing guidance, and residue or clearance concerns that influence both clinical protocol design and regulatory labeling.

Based on Application, use-case specificity is paramount; Behavioral Management, Diagnostic Procedures, and Surgical Procedures each impose unique efficacy and safety requirements, leading to differentiated product positioning and educational needs. Based on Distribution Channel, the landscape includes Online Pharmacies, Retail Pharmacies, Veterinary Clinics, and Veterinary Hospitals, with Online Pharmacies further delineated into Manufacturer Website and Third-Party Website, and Retail Pharmacies further divided into Chain Pharmacies and Independent Pharmacies, all of which influence purchasing behavior, margin structures, and point-of-care accessibility. Finally, Based on End User, the roles of Research Institutes, Veterinary Clinics, Veterinary Drug Distributors, and Veterinary Hospitals determine demand profiles, procurement cycles, and expectations for technical support and post-sale services.

A cross-regional perspective on how regulatory regimes clinical practice maturity and cultural attitudes across the Americas Europe Middle East & Africa and Asia-Pacific influence product strategies

Regional dynamics continue to shape clinical practice, regulatory frameworks, and commercial models for sedative agents. In the Americas, a mature veterinary infrastructure and strong private clinic networks drive demand for advanced formulations and practice-level services, while regulatory oversight and stakeholder expectations emphasize pharmacovigilance and controlled-substance management. In Europe, Middle East & Africa, heterogeneity is pronounced: regulatory stringency and welfare standards in parts of Europe contrast with developing-market needs across some Middle Eastern and African jurisdictions, which affects access models, pricing strategies, and the pace of clinical guideline harmonization.

In the Asia-Pacific region, rapid expansion of veterinary services, rising pet ownership, and growing investments in livestock production create opportunities for broader adoption of diverse sedative modalities, yet pricing sensitivity and fragmented distribution can limit uptake of higher-cost innovations. Across all regions, local regulatory landscapes, cultural attitudes toward animal care, and the maturity of veterinary education systems play decisive roles in the diffusion of new products and protocols. Consequently, region-specific go-to-market strategies, regulatory engagement plans, and clinician education initiatives are crucial for any organization seeking sustainable presence across these geographies.

Key competitive and partnership trends among manufacturers distributors and clinical stakeholders that are determining product differentiation and go-to-market effectiveness in the sedatives arena

Competitive dynamics in the animal sedative space reflect a mixture of established veterinary pharmaceutical manufacturers and specialized innovators. Industry leaders emphasize robust clinical trial programs, comprehensive safety data, and strong regulatory dossiers to support adoption among veterinarians and institutional purchasers. Concurrently, a cohort of agile players is advancing niche formulations, novel delivery mechanisms, and companion diagnostic tools that aim to differentiate on ease-of-use, safety, and species-specific performance.

Strategic partnerships between manufacturers and distribution networks, as well as alliances with veterinary professional associations and academic centers, are increasingly common to accelerate clinical validation and guideline incorporation. Mergers and selective licensing deals continue to shape the landscape, enabling companies to broaden portfolios and access new geographic channels. For stakeholders, the imperative is to combine scientific rigor with pragmatic commercialization tactics, ensuring that product claims are substantiated, post-market surveillance is robust, and clinician support programs address real-world administration and monitoring challenges.

Actionable strategic priorities for manufacturers distributors and clinical leaders focused on evidence building supply chain resilience regulatory engagement and channel-optimized commercialization

Leaders in the sector should prioritize a balanced agenda that integrates clinical evidence generation, regulatory foresight, and supply chain resilience. Investing in rigorous comparative studies and real-world evidence will strengthen product value propositions and facilitate guideline inclusion. At the same time, proactive regulatory engagement focused on labeling, residue management for food-producing animals, and controlled-substance compliance will reduce market access risk and enhance stakeholder trust. Operationally, establishing diversified manufacturing footprints and contingency sourcing arrangements can mitigate the impact of trade policy changes and tariff volatility.

Commercially, firms should tailor distribution strategies to the channel dynamics identified earlier, ensuring that online and retail pathways complement clinic- and hospital-based access, while providing education and technical support to end users. Collaborative initiatives with veterinary training programs and professional societies can accelerate adoption and standardize protocols. Finally, embedding digital tools for dosing decision support and post-procedure monitoring will improve clinical outcomes and create differentiation, making it easier to demonstrate the practical benefits of specific sedative solutions to both clinicians and institutional purchasers.

A clear explanation of the mixed-methods research approach combining practitioner interviews clinical literature regulatory review and cross-validation to ensure robust and reproducible insights

This analysis synthesizes a mixed-methods approach integrating primary qualitative inputs and rigorous secondary research to ensure comprehensive coverage and verifiable conclusions. Primary research involved structured interviews with practicing veterinarians, clinical pharmacologists, distribution executives, and procurement specialists to capture first-hand perspectives on product performance, procurement constraints, and evolving clinical protocols. These insights were triangulated with secondary sources including peer-reviewed literature, regulatory guidance documents, and product labeling to validate clinical assertions and safety considerations.

Data integrity was reinforced through cross-validation across multiple stakeholder groups and regions, with attention to methodological transparency and reproducibility. Where possible, comparative analyses focused on publicly available clinical data, pharmacokinetic profiles, and regulatory records to support claims about relative advantages and implementation considerations. Limitations include variability in reporting standards across jurisdictions and the evolving nature of regulatory guidance, which the methodology addresses through periodic updates and sensitivity checks to maintain relevance and accuracy over time.

A synthesis of strategic imperatives and practical takeaways that emphasize evidence alignment regulatory preparedness and distribution agility as drivers of durable success

The collective findings underscore a consistent theme: success in the animal sedative domain depends on aligning clinical performance with regulatory compliance and pragmatic distribution practices. Stakeholders must navigate species-specific requirements, application-driven performance expectations, and geographically diverse regulatory regimes while maintaining operational agility that addresses supply chain and tariff-related risks. Integrating evidence generation with clinician education and channel-specific commercialization will be central to driving adoption and ensuring long-term clinical and commercial viability.

Looking ahead, organizations that invest in robust safety and efficacy data, cultivate strategic partnerships across distribution and clinical education networks, and implement flexible supply strategies will be best positioned to respond to changing regulatory and market conditions. In essence, a coordinated approach that marries scientific credibility with practical execution will deliver the greatest benefit to animal health professionals and the animals they serve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Sedative Market, by Product Type

  • 8.1. Inhalant
  • 8.2. Injectable
  • 8.3. Oral

9. Animal Sedative Market, by Animal Type

  • 9.1. Companion Animals
  • 9.2. Equine
  • 9.3. Livestock

10. Animal Sedative Market, by Application

  • 10.1. Behavioral Management
  • 10.2. Diagnostic Procedures
  • 10.3. Surgical Procedures

11. Animal Sedative Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Animal Sedative Market, by End User

  • 12.1. Research Institutes
  • 12.2. Veterinary Clinics
  • 12.3. Veterinary Drug Distributors
  • 12.4. Veterinary Hospitals

13. Animal Sedative Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Sedative Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Sedative Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Animal Sedative Market

17. China Animal Sedative Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aspen Veterinary Resources, Ltd.
  • 18.6. Bayer AG
  • 18.7. Bimeda Holdings PLC
  • 18.8. Ceva Sante Animale
  • 18.9. Chanelle Pharma Group
  • 18.10. Dechra Pharmaceuticals PLC
  • 18.11. Huvepharma EOOD
  • 18.12. Jurox Pty Ltd.
  • 18.13. Merck & Co., Inc.
  • 18.14. Norbrook Laboratories Limited
  • 18.15. Orion Corporation
  • 18.16. Vetoquinol S.A.
  • 18.17. Virbac SA
  • 18.18. Vetoquinol S.A.
  • 18.19. Wildlife Pharmaceuticals, Inc.
  • 18.20. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL SEDATIVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL SEDATIVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INHALANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INHALANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INHALANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY BEHAVIORAL MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY BEHAVIORAL MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY BEHAVIORAL MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY DRUG DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY DRUG DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY DRUG DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)